Inhibition of colonic aberrant crypt foci by curcumin in rats is affected by age

Nutrition and Cancer

Volumn 48, Issue 1, 2004, Pages 37-43

  Kwon, Youngjoo ^a   Malik, Minnie ^a   Magnuson, Bernadene A ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; CHOLESTEROL; CURCUMIN; CYCLOOXYGENASE 2; MESSENGER RNA;

ABERRANT CRYPT FOCI; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CHOLESTEROL BLOOD LEVEL; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; MALE; NONHUMAN; PRECANCER; PROTEIN EXPRESSION; RAT;

ANIMALIA;

EID: 3042686650     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/s15327914nc4801_6     Document Type: Article

References (35)

1. Key TJ, Allen NE, Spencer EA, and Travis RC: The effect of diet on risk of cancer. Lancet 360, 861-868, 2002.
2. Bruce WR, Giacca A, and Medline A: Possible mechanisms relating diet and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 9, 1271-1279, 2000.
3. Ammon HP and Whal MA: Pharmacology of Curcuma longa. Planta Med 57, 1-7, 1991.
4. Rao CV, Rivenson A, Simi B, and Reddy BS: Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 55, 259-266, 1995.
5. Kawamori T, Lubet R, Steele VE, Kelloff GJ, Kaskey RB, et al.: Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 59, 597-601, 1999.
6. Mahmound NN, Carothers AM, Grunberger D, Bilinski RT, Churchill MR, et al.: Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis 21, 921-927, 2000.
7. min mice. Carcinogenesis 22, 821-825, 2001.
8. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, et al.: Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7, 1894-1900, 2001.
9. Lee HM, Greeley GH Jr, and Englander EW: Effects of aging on expression of genes involved in regulation of proliferation and apoptosis in the colonic epithelium. Mech Ageing Dev 115, 139-155, 2000.
10. Manzano VM, Puyol MR, Puyol DR, and Cazana FJ: Tretinoin prevents age-related renal changes and stimulates antioxidant defenses in cultured renal mesangial cells. J Pharmacol Exp Ther 289, 123-132, 1999.
11. Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, et al.: Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 61, 1058-1064, 1999.
12. Magnuson BA, Carr I, and Bird RP: Ability of aberrant crypt foci characteristics to predict colonic tumor incidence in rats fed cholic acid. Cancer Res 53, 4499-4504, 1993.
13. Hemler M and Lands WE: Purification of the cyclooxygenase that forms prostaglandins. Demonstration of two forms of iron in the holoenzyme. J Biol Chem 251, 5575-5579, 1976.
14. Prescott SM and Fitzpatrick FA: Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 1470, M69-M78, 2000.
15. Goel A, Boland CR, and Chauhan DP: Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 172, 111-118, 2001.
16. Zhang F, Altorki NK, Mestre JR, Subbaramaiah K, and Dannenberg AJ: Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 20, 445-451, 1999.
17. Rao CV, Simi B, and Reddy BS: Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis 14, 2219-2225, 1993.
18. Ramirez-Tortosa MC, Mesa MD, Aguilera MC, Quiles JL, Baro L, et al.: Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. Atherosclerosis 147, 371-378, 1999.
19. Soni KB and Kuttan R: Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol 36, 273-275, 1992.
20. Bird RP: Further investigation of the effect of cholic acid on the induction, growth characteristics and stability of aberrant crypt foci in rat colon. Cancer Lett 88, 201-209, 1995.
21. Magnuson BA, South EH, Exon JH, Dashwood RH, Xu M, et al.: Increased susceptibility of adult rats to azoxymethane-induced aberrant crypt foci. Cancer Lett 161, 185-193, 2000.
22. Verghese M, Rao DR, Chawan CB, and Shackelford L: Dietary inulin suppresses azoxymethane-induced preneoplastic aberrant crypt foci in mature Fisher 344 rats. J Nutr 132, 2804-2808, 2002.
23. Xu M, Chen R, and Dashwood RH: Effect of carcinogen dose fractionation, diet and source of F344 rat on the induction of colonic aberrant crypts by 2-amino-2-methylimidazo[4,5-f]quinoline. Carcinogenesis 20, 2293-2298, 1999.
24. Chung H, Wu D, Gay R, Han SN, Goldin B, et al.: Effect of age on susceptibility to azoxymethane-induced colonic aberrant crypt foci formation in C57BL/6JNIA mice. J Gerontol A Biol Sci Med Sci 58, B400-B405, 2003.
25. Dix D: On the role of genes relative to the environment in carcinogenesis. Mech Ageing Dev 124, 323-332, 2003.
26. Magnuson BA, Shirtliff N, and Bird RP: Resistance of aberrant crypt foci to apoptosis induced by azoxymethane in rats chronically fed cholic acid. Carcinogenesis 15, 1459-1462, 1994.
27. Dybing E and Soderlund EJ: Situations with enhanced chemical risks due to toxicokinetic and toxicodynamic factors. Regul Toxicol Pharmacol 30, S27-S30, 1999.
28. Asai A and Miyazawa T: Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma. Life Sci 67, 2785-2793, 2000.
29. Ireson CR, Jones DJ, Off S, Coughtrie MW, Boocock DJ, et al.: Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 11, 105-111, 2002.
30. Pan MH, Huang TM, and Lin JK: Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27, 486-494, 1999.
31. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, et al.: Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64, 353-356, 1998.
32. Sharma RA, Ireson CR, Verschoyle RD, Hill KA, Williams ML, et al.: Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clin Cancer Res 7, 1452-1458, 2001.
33. Harris WS: n-3 fatty acids and serum lipoproteins: animal studies. Am J Clin Nutr 65, 1611S-1616S, 1997.
34. Mela DJ, Cohen RS, and Kris-Etherton PM: Lipoprotein metabolism in a rat model of diet-induced adiposity. J Nutr 117, 1655-1662, 1987.
35. Takahashi M, Mutoh M, Kawamori T, Sugimura T, and Wakabayashi K: Altered expression of β-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis. Carcinogenesis 21, 1319-1327, 2000.